CClinicalTrials.gg
CompletedNCT03403179Updated Feb 28, 2019

Functional Remediation for Bipolar Disorder

An interventional study of Functional Remediation in Bipolar Disorder, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-02-28.

Sponsored by University of Michigan · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Bipolar Disorder is a major mood disorder with periodic mood episodes that may be very distressing, both to the individual and to others. When ill, the person is at particular risk for disruptions to social and occupational functioning, physical health, and even premature death. When not in an episode, individuals with BD may still be feeling well but have ongoing neurobiological processes, as well as the psychological sequelae from illness episodes, that can lead to subtle neurocognitive impairment that impedes overall functioning. This study is a test of an existing, published intervention that ameliorates deficits in functioning in euthymic bipolar individuals.

02

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Cognition
  • Cognitive Remediation
  • Mood Disorder
  • Functional Impairment
  • Psychosocial intervention
03

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • diagnosis of bipolar I or II disorder (BD), as determined by a structured diagnostic interview
  • at least three months of clinical remission (euthymia or minimal symptoms), based on the phone screen assessing mood episodes in the prior three months
  • score greater than 11 on a measure of everyday functioning (FAST; described in measures section) indicating at least mild impairment
  • use of a standard bipolar mood-stabilizing medication at the same, adequate dose (according to CANMAT treatment guidelines) for at least 3 months prior to screening, with ability to continue that dose during the study.

Exclusion criteria

Exclusion Criteria:

  • history of neurological illness or injury (e.g., stroke, brain tumor)
  • documented intellectual disability
  • inability to provide written informed consent
  • substance dependence within last 3 months or substance abuse in last 30 days
  • inability to complete the six-month intervention
  • received ECT in the past 12 months
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Receiving Psychosocial Intervention

    Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.

    Other: Functional Remediation

Interventions

  • OtherFunctional Remediation

    Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.

05

What researchers measure

Primary outcomes

  1. Feasibility

    Feasibility will be determined by a composite of ability to recruit and deliver the treatment intervention to both cohorts of participants, with adequate delivery of the intervention as measured by completion of the manual's objectives.

    Time frame: 30 weeks

  2. Acceptability (Subject Satisfaction)

    Acceptability of the intervention will be measured by use of the Satisfaction with Therapy and Therapist Scale.

    Time frame: 30 weeks

  3. Acceptability (Subject completion)

    Measured by percentage of subjects who complete the intervention.

    Time frame: 30 weeks

Secondary outcomes

  1. Functional Impact

    The Functioning Assessment Short Test (FAST) is an interviewer-administered scale for disability due to psychiatric illness, used both pre-and post-completion. The instrument has 24 items capturing 6 domains of functioning: (1) Autonomy (2) Occupational Functioning (3) Cognitive Functioning (4) Financial Issues (5) Relationships (6) Leisure Time. Scores above 11 identify at least mild functional impairment. Impact of the intervention on change in FAST score will be examined.

    Time frame: 30 weeks

06

Study locations

1 site
  • University of Michigan Depression Center
    Ann Arbor, Michigan 48109, United States
07

Registry details

Key details

Study ID
NCT03403179
Lead sponsor
University of Michigan
Responsible party
Sagar Parikh (Professor of Psychiatry, University of Michigan) — Principal investigator
First posted
Jan 18, 2018
Start date
Nov 17, 2017
Primary completion
Dec 10, 2018
Completion
Dec 20, 2018
Last update
Feb 28, 2019

Study contacts

Sagar Parikh, MD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion